COVID-19
COVID-19 is an infectious disease caused by the coronavirus SARS-CoV-2, which can lead to severe respiratory illness, especially in individuals at high risk.
COVID-19: Ibuzatrelvir Study for High-Risk Patients
We are investigating whether ibuzatrelvir can help reduce symptoms and prevent severe illness in non-hospitalized adults and adolescents with COVID-19. This study compares the medication to a placebo to see how effective it is.
3-6 months6-10 visitsConfirmation phase (III)Cost ReimbursementPartially RemoteInvestigational MedicinesOralInfectious DiseasesInternal Medicine
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 12 and 18 years old and weigh at least 40 kg, or are you 18 years or older?
- Have you tested positive for COVID-19 within the last day using a nasal test?
- Do you currently need or expect to need hospitalization due to severe COVID-19 symptoms?
- Have you received any antiviral treatment for COVID-19 in the last 30 days?
- Have you received a COVID-19 vaccine in the last 4 months?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Ibuzatrelvir
PF-07817883
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Anima
Alken, Belgium
Pneumocare
Jambes, Belgium
Specialized Hospital For Active Treatment Of Pulmonary Diseases Troyan EOOD
Department of Pneumology
Kyustendil, Bulgaria
Sponsor: Pfizer Inc.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.